



**FIGURE 1**

Subjective Drug Effects Scale: Liking This Feeling  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means




**FIGURE 2**

Subjective Drug Effects Scale: Liking This Feeling  
Area Under the Curve for Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means




**FIGURE 3**

Subjective Drug Effects Scale: Good Effects  
Maximum Change from Baseline (PDmax)  
Population: Valid for pharmacodynamic  
treatment-by-period Means




**FIGURE 4**

Subjective Drug Effects Scale: Good Effects  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Interaction




**FIGURE 5**

Subjective Drug Effects Scale: Feeling Sick  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-period Means



**FIGURE 6**


Subjective Drug Effects Scale: Feeling Sick  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: ●-●-● NTX Placebo ○-○-○ 0.0625 mg NTX ○-○-○ 0.0650 mg NTX

**FIGURE 7**


Subjective Drug Effects Scale: Bad Effects  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
treatment-by-period Means



Treatment: ●-●-● NTX Placebo ○-○-○ 0.25 mg NTX ◊-◊-◊ 0.50 mg NTX

**FIGURE 8**


Subjective Drug Effects Scale: Bad Effects  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment:   
 NTX placebo   
 25 mg NTX   
 50 mg NTX

**FIGURE 9**

Subjective Symptom Rating Scale: Antagonist  
Maximum Change from Baseline (pDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



**FIGURE 10**

Subjective Symptom Rating Scale: Antagonist  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means






FIGURE 11

Pupil Diameter (mm)  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



**FIGURE 12**

Pupil Diameter (mm)  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: •-•-• NTX Placebo 0-0-0 25 mg NTX 0-0-0 50 mg NTX